REFRACTORY LUPUS NEPHRITIS
Clinical trials for REFRACTORY LUPUS NEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LUPUS NEPHRITIS trials appear
Sign up with your email to follow new studies for REFRACTORY LUPUS NEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy aims to reset immune system in devastating autoimmune diseases
Disease control Recruiting nowThis study is testing a new cell therapy called CD19-BCMA CAR-T for people with severe autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy is safe and can help control diseases like lupus affecting the kidneys, systemic sclerosis, an…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Revolutionary Cancer-Fighting therapy tested for devastating autoimmune diseases
Disease control Recruiting nowThis study is testing a new cell therapy, originally developed for cancer, for people with severe autoimmune diseases that haven't responded to standard treatments. It uses modified immune cells (CAR-T) from umbilical cord blood to try to reset the body's faulty immune system. Th…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
15-Year watch begins for patients who received experimental autoimmune therapy
Knowledge-focused Recruiting nowThis study is tracking the long-term safety and effects of an experimental cell therapy called KYV-101 in people who have already received it. Researchers will follow 70 participants for up to 15 years to check for any delayed side effects and see how long the treatment's effects…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:47 UTC